scholarly journals tocilizumab in the treatment of systemic inflammatory response in a patient with CoVID-19 (clinical case)

2020 ◽  
Vol 12 (3) ◽  
pp. 90-93
Author(s):  
D. D. Avdoshina ◽  
A. G. Dyachkov ◽  
D. A. Gusev
Keyword(s):  
Monoclonal Antibody ◽  
Inflammatory Response ◽  
Clinical Experience ◽  
Interleukin 6 ◽  
Clinical Case ◽  
Saint Petersburg ◽  
Humanized Monoclonal Antibody ◽  
Anticytokine Therapy ◽  
Human Receptor

Improving the approaches to treating COVID-19 infection opens up the possibility for using previously known groups of drugs that demonstrate their effectiveness in the pathogenetic treatment of this disease. Significant clinical experience in the field of treatment of COVID-19 have been accumulated in Clinical Infectious Diseases Hospital named after S.P. Botkin, Saint-Petersburg, Russia. The case study demonstrates the timeliness and effectiveness of anticytokine therapy with COVID-19, the possibility of using a recombinant humanized monoclonal antibody to the human receptor for interleukin-6 (IL-6) (tocilizumab).

DRUG-INDUCED ENCEPHALOPATHY WITH IMPAIRED COGNITIVE FUNCTIONS DURING TOCILIZUMAB USE

2019 ◽  
Vol 57 (4) ◽  
pp. 482-485 ◽  
Author(s):  
P. A. Shesternya ◽  
S. V. Prokopenko ◽  
E. Yu. Mozheiko ◽  
O. D. Gritsenko ◽  
T. V. Tupaeva ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Cognitive Dysfunction ◽  
Cognitive Functions ◽  
Interleukin 6 ◽  
Clinical Case ◽  
Adverse Reactions ◽  
Biological Effects ◽  
Drug Induced ◽  
Receptor Monoclonal Antibody

Blockade of interleukin-6 (IL-6) is one of the most promising areas in the treatment of a number of immunoinflammatory diseases. Tocilizumab (TCZ), the first registered anti-IL-6 receptor monoclonal antibody, has been used effectively by rheumatologists since 2010. During this period, the spectrum of adverse reactions (ARs) of TCZ has been clearly defined. However, the multifaceted biological effects of IL-6 determine the probability of unexpected ARs. The article describes a clinical case of drug-induced encephalopathy with cognitive dysfunction during TCZ therapy.

scholarly journals Use of tocilizumab in the combination treatment of a COVID-19 patient with concomitant rheumatoid arthritis (a case report)

2021 ◽  
Vol 23 (5) ◽  
pp. 739-748
Author(s):  
V. A. Vizir ◽  
A. S. Sadomov ◽  
O. V. Demidenko
Keyword(s):  
Rheumatoid Arthritis ◽  
Monoclonal Antibody ◽  
Combination Treatment ◽  
Interleukin 6 ◽  
Clinical Case ◽  
Clinical Laboratory ◽  
Cytokine Storm ◽  
X Ray ◽  
Interleukin 6 Receptor ◽  
Receptor Monoclonal Antibody

The aim is to familiarize practitioners with the clinical case of tocilizumab use in the combination treatment of the coronavirus disease (COVID-19) patient with concomitant rheumatoid arthritis. Materials and methods. The clinical case shows our own follow-up of COVID-19 clinical course in the patient with concomitant rheumatoid arthritis during combination treatment with the use of a recombinant humanized anti-interleukin-6 receptor monoclonal antibody tocilizumab. Results. The patient with a severe COVID-19 course, whose examination and treatment results are given in the article, was comorbid for rheumatoid arthritis. The cytokine storm development at the hospital stage was confirmed by an increase in markers of systemic inflammation: C-reactive protein, D-dimer, fibrinogen, an almost 50-fold increase in serum interleukin-6 level, as well as absolute and relative lymphocytopenia. Despite the anti-inflammatory therapy administered with systemic corticosteroids, the patient’s condition progressively worsened. After assessing the indications and contraindications, it was decided to use the interleukin-6 receptor inhibitor tocilizumab, followed by rapid clinical, laboratory and X-ray positive response to the treatment. The understanding of tocilizumab use in patients with COVID-19 at the current stage was formed based on the comparative analysis of our own clinical case data and the results of relevant clinical trials, world recommendations and guidelines. Conclusions. The use of recombinant humanized anti-interleukin-6 receptor monoclonal antibody tocilizumab in the combination treatment of severe COVID-19 with concomitant rheumatoid arthritis is pathogenetically based and decreases the main clinical and laboratory signs of cytokine storm, respiratory failure, improves chest x-ray findings and reduces the length of hospital stay. Further large randomized placebo-controlled trials including the population of patients with various comorbid conditions are needed to clarify conclusively the place and role of anti-cytokine drugs in the treatment of COVID-19 patients.

scholarly journals Experience with the use of recombinant humanized monoclonal antibodies to the human receptor for interleukin-6 in patients with CoVID-19

2020 ◽  
Vol 12 (3) ◽  
pp. 28-33 ◽  
Author(s):  
D. А. Gusev ◽  
М. А. Vashukova ◽  
I. P. Feduniak ◽  
V. B. Musatov ◽  
V. A. Kapatsyna
Keyword(s):  
Interleukin 6 ◽  
Careful Analysis ◽  
Global Challenge ◽  
Reactive Protein ◽  
Humanized Monoclonal Antibody ◽  
Pathogenetic Therapy ◽  
Duration Of Hospitalization ◽  
Coronavirus Infection ◽  
Severity Of The Disease ◽  
Human Receptor

The new coronavirus infection (COVID-19) has become a truly global challenge for all of humanity, and, above all, for the healthcare system. Among its most important aspects requiring careful analysis are the clinical and laboratory features of the course of the disease, which make it possible to determine approaches to pathogenetic therapy in severe forms of the disease. Materials and methods. A retrospective analysis of medical records of patients (n = 31) of severe COVID-19 patients who were hospitalized in St. Petersburg City Clinical Hospital for Infectious Diseases named after S.P. Botkin ”in March – May 2020. Clinical and laboratory characteristics were evaluated, including the level of ferritin, C-reactive protein, D-dimer, interleukin-6, depending on the severity of the disease. The criteria for the appointment of a recombinant humanized monoclonal antibody to the human receptor for interleukin-6 (INN – tocilizumab) in patients with a severe course of the disease and its effectiveness are determined. Results. In the treatment of severe patients with COVID-19, it is necessary to carefully evaluate the clinical picture of the course of the disease, which may be ahead of changes in laboratory parameters. The introduction of tocilizumab leads to a rapid regression of general infectious symptoms, subjective and objective manifestations of respiratory failure and, as a consequence, a decrease in the duration of hospitalization. It is extremely important that the drug is administered in a timely manner during the rise of the “cytokine storm”. The time for optimal administration of tocilizumab begins from 8-9 days from the onset of the disease, until the patient is transferred to mechanical ventilation.

Successful Treatment of Refractory Takayasu Arteritis with Tocilizumab—A Case Report

2018 ◽  
Vol 1 (2) ◽  
pp. 133-135
Author(s):  
Nambiar Vivek K. ◽  
T.S. Dhanya ◽  
Ajai Amrutha V.
Keyword(s):  
Monoclonal Antibody ◽  
Case Report ◽  
Successful Treatment ◽  
Takayasu Arteritis ◽  
Interleukin 6 ◽  
Biological Agents ◽  
Young Females ◽  
Duration Of Therapy ◽  
Humanized Monoclonal Antibody ◽  
Interleukin 6 Receptor

Takayasu arteritis (TA) is an idiopathic inflammatory vasculitis mostly affecting young females in the second or third decades of life. Corticosteroids and conventional immunosuppressants remain the mainstay of treatment for TA, but refractory cases are dealt with biological agents. The high cost and longer duration of therapy are issues of concern. Here, we report a case of a patient with refractory TA who underwent successful treatment with tocilizumab, a humanized monoclonal antibody against interleukin-6 receptor.

scholarly journals Lung transplantation for idiopathic multicentric Castleman disease: potential efficacy and tolerability of a humanized anti-interleukin-6 receptor monoclonal antibody

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Yasuaki Tomioka ◽  
Shinji Otani ◽  
Shin Tanaka ◽  
Kazuhiko Shien ◽  
Ken Suzawa ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Lung Transplantation ◽  
Interleukin 6 ◽  
De Novo ◽  
Lymphoproliferative Disease ◽  
Castleman Disease ◽  
Multicentric Castleman Disease ◽  
Humanized Monoclonal Antibody ◽  
Interleukin 6 Receptor ◽  
End Stage

Abstract Background Idiopathic multicentric Castleman disease (iMCD) is a rare polyclonal lymphoproliferative disease caused by the overrepresentation of interleukin-6 (IL-6). Tocilizumab (TCZ) is a humanized monoclonal antibody that binds to the IL-6 receptor and is approved for the treatment of iMCD. The efficacy and tolerability of TCZ in patients with iMCD undergoing lung transplantation (LTx) remain unknown. Case presentation We present the case of a 48-year-old iMCD patient with end-stage lung disease (ESLD) who was successfully treated with cadaveric single-LTx. Intravenous TCZ was used to stabilize the iMCD patient every 2 weeks, except for withdrawal immediately after LTx. At 32 month post-transplant, the patient remained asymptomatic without evidence of rejection, development of de novo donor-specific antibody (DSA), and recurrent iMCD in the native lung. Conclusions Single-LTx can be a feasible treatment option for ESLD caused by iMCD. TCZ can be used safely and may be beneficial in recipients with iMCD, and TCZ in combination with usual immunosuppression can be helpful in stabilizing iMCD patients pre- and post-LTx.

The Variable Nature of Stuttering: A Clinical Case Study

1995 ◽  
Vol 22 ◽  
pp. 29-35
Author(s):  
Jennifer Gutierrez ◽  
Anthony Caruso
Keyword(s):  
Clinical Case ◽  
Clinical Case Study ◽  
Variable Nature
Sign in / Sign up

Export Citation Format

Share Document